Monitoring of the pharmacological treatment availability in patients with multiple sclerosis in the Greater Poland population

Abstract

IntroductionThere is no clear explanation for the availability of multiple sclerosis (MS) pharmacological treatment for patients in Greater Poland and it can be assumed that the same reason is common in most of the developed countries in the United Europe. As an autoimmune disease MS can overlap with other diseases especially rheumatic disease (RD) as well as some feature of RD may mimic MS, such as MS-like syndrome in the course of primary Sjögren’s syndrome. Therefore proper diagnosis and sufficient treatment of MS is important not only for neurologists but also for other clinicians including rheumatologists. The study aims to provide insights that could help healthcare managers create more effective logistical guidelines to improve the timely initiation of pharmacological treatment for MS.Material and MethodsThe analysis of the treatment of MS patients has been conducted on a group of 500 patients who were under the management of one healthcare center in Greater Poland.ResultsThe results point to the different factors influencing the delay in the undertaking the pharmacological treatment, among others the age of the patient, waiting time for clinical evaluation and the final diagnosis from first symptoms to diagnosis, and the patient’s waiting time from diagnosis to referral for qualification for treatment.ConclusionsThe outcomes of this study have the potential to serve as a valuable resource for healthcare managers. The study’s findings could be used as a foundation for developing logistical guidelines aimed at enhancing the pharmacological treatment of MS patients. Furthermore, the study suggests that the reasons behind treatment delays in MS patients might be prevalent in many countries across the United Europe region. However, it’s important to note that confirming this conclusion requires additional comparative studies.